"The data to be presented at the ASGCT meeting demonstrate the development and validation of uniQure's technologies to improve gene therapy as a therapeutic approach, and supports our aim to rapidly bring new disease-modifying therapies to patients with severe genetic diseases," stated Matthew Kapusta, chief executive officer of uniQure.
Harald Petry, Ph.D., chief scientific officer at uniQure, added, "We are making strong progress in advancing the preclinical development of AMT-130 in Huntington's disease, and further enhancing AAV vector technology and the potential for re-administration protocols, which continue to provide compelling evidence of our modular platform."
Specific details on uniQure's presentations at ASGCT include:
Investor and Analyst Breakfast
uniQure management will host an investor and analyst breakfast meeting featuring members of the research and development team to review the data presented during ASGCT.
|Date and Time:||Friday, May 12, 2017 at 7:00 am EDT|
|Location:||Omni Shoreham Hotel, The Congressional Room, 2500 Calvert Street NW, Washington, DC.|
|The Omni Shoreham hotel is located directly across the conference venue.|
To request attendance at the meeting, please RSVP to Investors@uniQure.com by May 5, 2017, as space is limited.
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with liver/metabolic, central nervous system and cardiovascular diseases. www.uniQure.com
uniQure Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the development of our gene therapy product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with collaboration arrangements, our and our collaborators' clinical development activities, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure's 2016 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2017. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.
To read more Press Release articles, click here.